logo-loader
RNS
viewAlliance Pharma PLC

Alliance Pharma PLC - Director's Dealing

RNS Number : 8757V
Alliance Pharma PLC
05 December 2019
 

ALLIANCE PHARMA PLC

("Alliance" or the "Group")

 

Director's Dealing

 

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, announces that it has received notice that on 2 December 2019, Andrew Franklin, Chief Financial Officer of Alliance, exercised options over 1,500,000 new ordinary shares of 1 pence each in the Company ("Ordinary Shares") under the Company's Share Option Plans. The average exercise price was 46.75 pence.

 

Following this exercise, on 5 December 2019, Mr Franklin sold 1,371,616 Ordinary Shares at a price of 76.9 pence per share, and in accordance with the Group's share retention policy, retained 128,384 Ordinary Shares. Following these transactions, Mr Franklin's total beneficial interest in the Group is 128,384 Ordinary Shares, representing approximately 0.02 per cent. of the Group's issued share capital.

 

The 1,500,000 Ordinary Shares will be admitted to trading pursuant to an existing block listing, and will rank pari passu with the existing Ordinary Shares in issue.

 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Andrew Franklin

2

Reason for the notification

a)

Position/status

Chief Financial Officer

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

ALLIANCE PHARMA PLC

b)

Legal Entity Identifier

213800RYIWZA4Q5WPZ13

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Ordinary shares of 1 pence each

 

 

GB0031030819

b)

Nature of the transaction

a)   Exercise of options

b)   Sale of Ordinary Shares

c)

Currency

GBP

d)

Price(s) and volume(s)

 

Price(s)

Volume(s)

a)   46.75 pence

1,500,000

b)   76.9 pence

1,371,616



e)

Aggregated information

- Aggregated volume

- Price

- Aggregated total

a) 1,500,000 options over Ordinary Shares, weighted average exercise price of 46.75 pence per Share.

b) 1,371,616 Ordinary Shares, sold at a price of 76.9 pence per Ordinary Share, totalling £1,054,773.

 

f)

Date of the transaction

2 December 2019 and 5 December 2019

g)

Place of the transaction

London Stock Exchange, AIM

 

 

For further information:

 

Alliance Pharma plc                                                     + 44 (0)1249 466966

Peter Butterfield, Chief Executive Officer

Andrew Franklin, Chief Financial Officer

www.alliancepharma.co.uk

 

Buchanan                                                                     + 44 (0)20 7466 5000

Mark Court / Sophie Wills / Hannah Ratcliff

 

Numis Securities Limited                                             + 44 (0)20 7260 1000

Nominated Adviser: Freddie Barnfield, Huw Jeremy

Corporate Broking: James Black

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHKMMGZDKVGLZM

Quick facts: Alliance Pharma PLC

Price: 70.5

Market: AIM
Market Cap: £374.41 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

'It's never been so busy and exciting', says Alliance Pharma PLC CEO

Alliance Pharma plc (LON:APH) said revenues had more than doubled and trading profits for the year to the end of December were in line with City forecasts as it provided investors with a progress report. The speciality pharma company said it expects sales to be £97.5mln - up from £48.3mln...

on 24/1/17